Seek Returns logo

TEVA vs. THC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at TEVA and THC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, THC is a standard domestic listing.

SymbolTEVATHC
Company NameTeva Pharmaceutical Industries LimitedTenet Healthcare Corporation
CountryIsraelUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsHealth Care Providers & Services
Market Capitalization20.76 billion USD16.08 billion USD
ExchangeNYSENYSE
Listing DateFebruary 16, 1982March 17, 1980
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of TEVA and THC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

TEVA vs. THC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolTEVATHC
5-Day Price Return-3.07%2.57%
13-Week Price Return-2.13%10.21%
26-Week Price Return1.54%40.39%
52-Week Price Return-11.44%11.16%
Month-to-Date Return8.44%12.82%
Year-to-Date Return-25.11%44.14%
10-Day Avg. Volume1.66M1.00M
3-Month Avg. Volume2.25M1.54M
3-Month Volatility25.51%36.54%
Beta0.821.53

Profitability

Return on Equity (TTM)

TEVA

-2.58%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

THC

37.25%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

THC’s Return on Equity of 37.25% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

TEVA vs. THC: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Net Profit Margin (TTM)

TEVA

-0.95%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

THC

7.17%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

A Net Profit Margin of 7.17% places THC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.

TEVA vs. THC: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Operating Profit Margin (TTM)

TEVA

5.38%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

THC

17.77%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

An Operating Profit Margin of 17.77% places THC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

TEVA vs. THC: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Profitability at a Glance

SymbolTEVATHC
Return on Equity (TTM)-2.58%37.25%
Return on Assets (TTM)-0.40%5.11%
Net Profit Margin (TTM)-0.95%7.17%
Operating Profit Margin (TTM)5.38%17.77%
Gross Profit Margin (TTM)50.88%82.36%

Financial Strength

Current Ratio (MRQ)

TEVA

1.06

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

THC

1.71

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

THC’s Current Ratio of 1.71 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

TEVA vs. THC: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

TEVA

2.52

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

THC

3.51

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

With a Debt-to-Equity Ratio of 3.51, THC operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

TEVA vs. THC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Interest Coverage Ratio (TTM)

TEVA

-0.38

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

THC

10.27

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

THC’s Interest Coverage Ratio of 10.27 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

TEVA vs. THC: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Financial Strength at a Glance

SymbolTEVATHC
Current Ratio (MRQ)1.061.71
Quick Ratio (MRQ)0.681.54
Debt-to-Equity Ratio (MRQ)2.523.51
Interest Coverage Ratio (TTM)-0.3810.27

Growth

Revenue Growth

TEVA vs. THC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

TEVA vs. THC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

TEVA

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

THC

0.00%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

THC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TEVA vs. THC: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Dividend Payout Ratio (TTM)

TEVA

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

THC

0.00%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

THC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TEVA vs. THC: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Dividend at a Glance

SymbolTEVATHC
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

TEVA

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for TEVA is currently unavailable.

THC

10.79

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

In the lower quartile for the Health Care Providers & Services industry, THC’s P/E Ratio of 10.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

TEVA vs. THC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

TEVA

1.25

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

THC

0.77

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

THC’s P/S Ratio of 0.77 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TEVA vs. THC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

TEVA

2.80

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

TEVA’s P/B Ratio of 2.80 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

THC

4.36

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

THC’s P/B Ratio of 4.36 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

TEVA vs. THC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Valuation at a Glance

SymbolTEVATHC
Price-to-Earnings Ratio (TTM)--10.79
Price-to-Sales Ratio (TTM)1.250.77
Price-to-Book Ratio (MRQ)2.804.36
Price-to-Free Cash Flow Ratio (TTM)18.487.24